Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392767 | 1.00 | GPR119 (0.51) | GPR119ALOX5APFEN1SLC2A1KDM4E | |
| SCHEMBL14376580 | 0.91 | GPR119 (0.50) | GPR119KDM4EPKMPOLBMET | |
| SCHEMBL14334489 | 0.88 | ALOX5AP (0.48) | GPR119ALOX5APFEN1 | |
| SCHEMBL14335007 | 0.85 | GPR119 (0.53) | GPR119POLBALDH1A1 | |
| SCHEMBL1475840 | 0.84 | GAA (0.54) | GPR119KDM4EPKMMETALDH1A1 | |
| SCHEMBL14334840 | 0.83 | ALOX5AP (0.53) | GPR119ALOX5APFEN1SLC2A1KDM4E | |
| SCHEMBL14334503 | 0.82 | POLB (0.45) | GPR119ALOX5APFEN1KDM4EPOLB | |
| SCHEMBL14285782 | 0.82 | FNTA (0.43) | GPR119ALOX5APFEN1METFAAH | |
| SCHEMBL14335034 | 0.82 | PIK3CD (0.52) | GPR119 | |
| SCHEMBL29913160 | 0.81 | SSTR4 (0.52) | GPR119ALOX5APFEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | GPR119 3223/4885ALOX5AP 2993/4885FEN1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.